{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:36:30Z","timestamp":1789076190092,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Yunnan Applied Basic Research Projects","award":["2018FE001(-145)"],"award-info":[{"award-number":["2018FE001(-145)"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chemical Neuroanatomy"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jchemneu.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T11:28:41Z","timestamp":1549020521000},"page":"66-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Visual impairment in neuromyelitis optica spectrum disorders (NMOSD)"],"prefix":"10.1016","volume":"97","author":[{"given":"Yan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianmei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchemneu.2019.01.012_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167473","article-title":"Retinal morphology and sensitivity are primarily impaired in eyes with neuromyelitis optica spectrum disorder (NMOSD)","volume":"11","author":"Akiba","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0025","first-page":"130","article-title":"Recurrent isolated optic neuritis: a study on 22 patients","volume":"16","author":"Arzani","year":"2017","journal-title":"Iran J. Neurol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/2051-5960-2-48","article-title":"Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury","volume":"2","author":"Asavapanumas","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-2094-11-16","article-title":"Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immunoglobulin G","volume":"11","author":"Asavapanumas","year":"2014","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0040","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0045","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1172\/JCI28334","article-title":"Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a devic-like disease in mice","volume":"116","author":"Bettelli","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0050","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bpa.12098","article-title":"Experimental models of neuromyelitis optica","volume":"24","author":"Bradl","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0060","first-page":"1638","article-title":"Macular changes of neuromyelitis optica through spectral-domain optical coherence tomography","volume":"9","author":"Cheng","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0065","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.autrev.2014.01.034","article-title":"Diagnosis and classification of neuromyelitis optica (Devic\u2019s syndrome)","volume":"13","author":"Drori","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0070","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12974-016-0746-9","article-title":"Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G","volume":"13","author":"Felix","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0080","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1212\/NXI.0000000000000135","article-title":"Acute optic neuritis: unmet clinical needs and model for new therapies","volume":"2","author":"Galetta","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0085","article-title":"Sex differences in autoimmune disorders of the central nervous system","author":"Gold","year":"2018","journal-title":"Semin Immunopathol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-2094-5-22","article-title":"Neuromyelitis optica pathogenesis and aquaporin 4","volume":"5","author":"Graber","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0095","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jneuroim.2006.05.019","article-title":"Retinal ganglion cell damage induced by spontaneous autoimmune optic neuritis in MOG-specific TCR transgenic mice","volume":"178","author":"Guan","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172168","article-title":"Optical coherence tomography angiography in eyes with good visual acuity recovery after treatment for optic neuritis","volume":"12","author":"Higashiyama","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1874364101206010065","article-title":"Optic neuritis, its differential diagnosis and management","volume":"6","author":"Hoorbakht","year":"2012","journal-title":"Open Ophthalmol. J."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0120","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40478-015-0207-1","article-title":"Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica","volume":"3","author":"Jones","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0125","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s00415-017-8606-9","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis","volume":"264","author":"Kang","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0135","first-page":"270","article-title":"Optic neuritis--immunological approach to elucidate pathogenesis and develop innovative therapy","volume":"117","author":"Kezuka","year":"2013","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/08820538.2016.1208761","article-title":"Aquaporin 4 antibody in the korean patient with New-onset optic neuritis","volume":"33","author":"Kim","year":"2018","journal-title":"Semin. Ophthalmol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2010.02.157","article-title":"Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells","volume":"394","author":"Kinoshita","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0155","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0160","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1172\/JCI28330","article-title":"Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell\/B cell cooperation","volume":"116","author":"Krishnamoorthy","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0165","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s13167-017-0102-x","article-title":"Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system","volume":"8","author":"Kuchling","year":"2017","journal-title":"EPMA J."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0170","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.nicl.2018.05.004","article-title":"Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system","volume":"19","author":"Kuchling","year":"2018","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0175","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-015-0259-2","article-title":"Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody","volume":"3","author":"Kurosawa","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin","year":"2013","journal-title":"Prog. Retin Eye Res."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0185","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12264-015-1552-6","article-title":"Experimental models of neuromyelitis optica: current status, challenges and future directions","volume":"31","author":"Li","year":"2015","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0190","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.nicl.2016.05.014","article-title":"Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica","volume":"11","author":"Manogaran","year":"2016","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12974-016-0577-8","article-title":"Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid","volume":"13","author":"Marignier","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171880","article-title":"Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritis","volume":"12","author":"Matsumoto","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0205","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1167\/iovs.08-1815","article-title":"Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica","volume":"49","author":"Merle","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0210","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0215","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1523\/JNEUROSCI.18-07-02506.1998","article-title":"Aquaporin-4 water channel protein in the rat retina and optic nerve: polarized expression in Muller cells and fibrous astrocytes","volume":"18","author":"Nagelhus","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0220","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.exer.2016.03.019","article-title":"Glio-vascular modifications caused by aquaporin-4 deletion in the mouse retina","volume":"146","author":"Nicchia","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0225","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1212\/NXI.0000000000000334","article-title":"Microstructural visual system changes in AQP4-antibody-seropositive NMOSD","volume":"4","author":"Oertel","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13167-017-0123-5","article-title":"Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy","volume":"9","author":"Oertel","year":"2018","journal-title":"EPMA J"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0235","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1177\/1352458515578888","article-title":"A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"21","author":"Outteryck","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0240","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0245","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/eye.2011.81","article-title":"Optic neuritis","volume":"25","author":"Pau","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0250","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/bjophthalmol-2016-309412","article-title":"Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography","volume":"101","author":"Peng","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0255","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrneurol.2014.108","article-title":"The investigation of acute optic neuritis: a review and proposed protocol","volume":"10","author":"Petzold","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0260","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0270","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/1352458513503053","article-title":"Visual evoked potentials in neuromyelitis optica and its spectrum disorders","volume":"20","author":"Ringelstein","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0275","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-008-0781-2","article-title":"Characteristics of Devic\u2019s disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"Schmidt","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066151","article-title":"Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis","volume":"8","author":"Schneider","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0290","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ane.13004","article-title":"Optical coherence tomography in acute optic neuritis: a population-based study","volume":"138","author":"Soelberg","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170847","article-title":"Retinal nerve fiber layer may Be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study","volume":"12","author":"Stiebel-Kalish","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0305","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/brain\/awr264","article-title":"Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis","volume":"135","author":"Syc","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0310","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0320","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0325","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14728222.2017.1398236","article-title":"The aquaporin-4 water channel as a potential drug target in neurological disorders","volume":"21","author":"Verkman","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0330","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0335","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0340","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1212\/NXI.0000000000000347","article-title":"Foveal thinning in neuromyelitis optica: a sign of retinal astrocytopathy?","volume":"4","author":"Yamamura","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0345","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0350","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-016-0355-y","article-title":"Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO\/SD","volume":"4","author":"Zeka","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0355","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-016-0355-y","article-title":"Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO\/SD","volume":"4","author":"Zeka","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0360","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen3.12345","article-title":"Muller cells and retinal axons can be primary targets in experimental neuromyelitis optica spectrum disorder","volume":"8","author":"Zeka","year":"2017","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0365","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jchemneu.2019.01.012_bib0370","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann. Neurol."}],"container-title":["Journal of Chemical Neuroanatomy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891061818301789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891061818301789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:37:59Z","timestamp":1760193479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891061818301789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":74,"alternative-id":["S0891061818301789"],"URL":"https:\/\/doi.org\/10.1016\/j.jchemneu.2019.01.012","relation":{},"ISSN":["0891-0618"],"issn-type":[{"value":"0891-0618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual impairment in neuromyelitis optica spectrum disorders (NMOSD)","name":"articletitle","label":"Article Title"},{"value":"Journal of Chemical Neuroanatomy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchemneu.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}